FDA
-
-
-
-
-
-
-
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Receives FDA “Study May Proceed” Notification for a Phase IIA Trial of AL001
-
-
-
-
-
-
-
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
-
-
-
-
-
-
-
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild
-
-
-
-
-
-
-
Alzamend Neuro (ALZN) Submits IND Application for Phase I/IIA Trial for an Immunotherapy ALZN002
-
-
-
-
-
-
-
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
-
322,238 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

